Athenex (Athenex) Net Margin % : -395.93% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Athenex's Net Income for the three months ended in Dec. 2022 was $-34.2 Mil. Athenex's Revenue for the three months ended in Dec. 2022 was $8.6 Mil. Therefore, Athenex's net margin for the quarter that ended in Dec. 2022 was -395.93%.

The historical rank and industry rank for Athenex's Net Margin % or its related term are showing as below:

ATNXQ's Net Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 3.76
* Ranked among companies with meaningful Net Margin % only.

Athenex Net Margin % Historical Data

The historical data trend for Athenex's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Net Margin % Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

Get a 7-Day Free Trial

-131.81

-122.25

-101.24

-209.47

-100.59

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Margin %	Get a 7-Day Free Trial															-2,549.76	-58.61	-102.03	-58.66	-395.93

Competitive Comparison of Athenex's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Athenex's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's Net Margin % distribution charts can be found below:

* The bar in red indicates where Athenex's Net Margin % falls into.

Athenex Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Athenex's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-103.427	/	102.821
	=	-100.59 %

Athenex's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-34.181	/	8.633
	=	-395.93 %

Athenex (OTCPK:ATNXQ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Athenex Net Margin % Related Terms

Thank you for viewing the detailed overview of Athenex's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (Athenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Executives

Jinn Wu	director	107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam	director, officer: CEO and Chairman of the Board
Joe Annoni	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook	officer: See Remarks	C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang	officer: Pres Cell Therapy, VP Corp Dev	C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan	director, officer: EVP, Chief Medical Officer	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski	officer: Chief Scientific Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams	officer: Interim Chief Acct Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell	director	3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo	officer: President, China	3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok	director	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203